For a patient beginning antihypertensive therapy, should he be started on monotherapy (one drug) or combination therapy (two drugs)?

Initial Antihypertensive Therapy: Monotherapy vs. Combination

For most patients beginning antihypertensive therapy with stage 2 hypertension (BP ≥140/90 mmHg), start with 2 medications as initial combination therapy, preferably in a single-pill combination. For stage 1 hypertension (BP 130-139/80-89 mmHg) with low cardiovascular risk, start with 1 medication.

Treatment Algorithm Based on Blood Pressure Level

Stage 2 Hypertension (BP ≥140/90 mmHg)

• Start with 2-drug combination therapy 1, 2
• Use single-pill combinations when available to improve adherence 1, 2
• Preferred combinations:
  • ACE inhibitor or ARB + calcium channel blocker (CCB)
  • ACE inhibitor or ARB + thiazide/thiazide-like diuretic
  • CCB + thiazide/thiazide-like diuretic 2

Stage 1 Hypertension (BP 130-139/80-89 mmHg)

• Start with monotherapy if low-moderate cardiovascular risk 1
• Consider 2-drug combination if:
  • High cardiovascular risk (≥10% 10-year ASCVD risk) 3
  • Presence of cardiovascular disease, chronic kidney disease, or diabetes 4, 5
  • BP is ≥20/10 mmHg above target 5, 6

Grade 1 Hypertension (BP 140-159/90-99 mmHg) - European Classification

• Start monotherapy in low-risk patients 7
• Start 2-drug combination immediately in high-risk patients (CVD, organ damage, diabetes) 7

Evidence Supporting Combination Therapy

The most recent and highest quality guidelines strongly favor initial combination therapy for most patients. The 2025 AHA/ACC guideline provides Class 1, Level B-R evidence that initiating with 2 first-line agents in stage 2 hypertension improves BP control and adherence 1. The 2024 ESC guideline similarly recommends combination therapy for most patients with confirmed hypertension (BP ≥140/90 mmHg) 2.

Real-world evidence demonstrates superior outcomes with initial combination therapy:

• A 2018 Italian study of 44,534 patients showed initial 2-drug fixed-dose combinations reduced cardiovascular hospitalizations by 21% compared to monotherapy, with even greater protection (56% reduction) when comparing periods of combination vs. monotherapy within the same patients 8
• Initial combination therapy dramatically reduces therapeutic inertia—patients starting with monotherapy had only 22-36% uptitration to combinations over 3 years, while those starting with combinations maintained multidrug therapy in 78-85% 9
• A 2017 randomized controlled trial demonstrated combination therapy reduced home systolic BP 4.9 mmHg more than sequential monotherapy over 32 weeks 10

Rationale for Combination Therapy

Monotherapy achieves target BP in only 20-30% of hypertensive patients 11, 7. The physiological basis for combination superiority includes:

• Combining drugs with complementary mechanisms produces additive BP reduction greater than dose escalation of single agents 11
• Lower doses of each drug in combinations reduce side effects compared to high-dose monotherapy 7
• Faster achievement of BP targets, particularly critical in high-risk patients where early BP control reduces cardiovascular events 7
• Single-pill combinations improve adherence and reduce dropout rates 11

Exceptions to Combination Therapy

Start with monotherapy in:

• Patients aged ≥85 years 2
• Frail elderly patients 4, 5
• Those with symptomatic orthostatic hypotension 2
• Stage 1 hypertension with low cardiovascular risk 1
• Patients at high risk for excessive BP lowering 5, 6

Common Pitfalls to Avoid

Do not combine:

• ACE inhibitor + ARB + renin inhibitor (Class 3 Harm recommendation) 1
• ACE inhibitor + ARB together (increases adverse events without additional benefit) 5, 6
• Non-dihydropyridine CCB + beta-blocker (risk of excessive bradycardia) 5, 6

Avoid therapeutic inertia: The sequential monotherapy approach leads to prolonged periods of uncontrolled BP because clinicians fail to uptitrate therapy. Only 36% of patients starting monotherapy receive combination therapy even after 3 years 9. This delay in achieving BP control translates to preventable cardiovascular events.

Preferred Drug Combinations

First-line two-drug combinations (in order of preference based on cardiovascular outcomes):

1. ACE inhibitor + CCB (strongest cardiovascular protection data) 12
2. ARB + CCB
3. ACE inhibitor or ARB + thiazide/thiazide-like diuretic
4. CCB + thiazide/thiazide-like diuretic 7, 2

The ACE inhibitor/CCB combination showed superior cardiovascular protection compared to beta-blocker/diuretic or ACE inhibitor/diuretic combinations in major trials 12.